期刊文献+

C反应蛋白联合4项肿瘤标志物检测肺癌的临床研究 被引量:8

Significance of 4 tumor markers and C-reactive for lung cancer
下载PDF
导出
摘要 目的:探讨CRP联合4项肿瘤标志物检测肺癌的临床价值。方法:随机选取我院2011年5月-2014年5月收治的50例肺癌患者、40例良性肺部疾病患者和30例健康志愿者为研究对象。取外周血检测CRP、CEA、CA125、CYFRA21-1、NSE含量。结果:肺癌组和肺良性疾病组CRP和CA125检测结果显著高于健康组,肺癌组CEA、NSE和CYFRA21-1水平显著高于肺良性疾病组和健康组,肺癌组CRP值显著低于肺良性疾病组,差异具有统计学意义(P<0.05)。肺癌不同病理组织分型中显示腺癌组CEA和CA125水平显著高于小细胞肺癌组和鳞癌组,小细胞肺癌组血清NSE水平显著高于腺癌组和鳞癌组,鳞癌组CYFRA21-1水平显著高于小细胞肺癌组,鳞癌组CA125水平显著低于小细胞肺癌组和腺癌组,差异具有统计学意义(P均<0.05)。患者血清CRP、CEA、CA125、NSE、CYFRA21-1单项检测敏感度均较低,特异性稍高,联合检测结果显示敏感度显著升高,但特异性有所下降。结论:C反应蛋白联合4项肿瘤标志物检测可以提高检测的敏感性,增高阳性检出率。 Objective:To investigate the C-reactive protein (CRP) combined with four tumor markers in lung cancer diagnosis.Methods:Randomly selected 50 cases of lung cancer,40 patients with benign lung disease and 30 healthy people,to detect CRP,CEA,CA125,CYFRA21-1,NSE.Results:In lung cancer patients and patients with benign lung disease CRP and CA125 were significantly higher than the healthy group.In lung cancer CEA,NSE and CYFRA21-1 were significantly higher than benign lung disease and healthy group.In lung cancer group CRP was significantly less than benign lung disease group,the difference was statistically significant (P < 0.05).For serum CRP,CEA,CA125,NSE,CYFRA21 single detection sensitivity were low,specificity higher.Combined test results showed a significant increase in sensitivity,but the specificity decreased.Conclusion:C-reactive protein combined four tumor markers can improve the sensitivity with higher positive rate.
出处 《现代肿瘤医学》 CAS 2015年第14期1985-1988,共4页 Journal of Modern Oncology
基金 广元市科技技术项目(编号:广科知发[2013]45号)
关键词 C反应蛋白 肿瘤标志物 肺癌 C-reactive protein tumor markers lung cancer
  • 相关文献

参考文献10

  • 1De - Torres JP, Wilson DO,Sanchez - Salcedo P,et al. Lung cancerin COPD patients : Development and validation of the COPD lungcancer screening score ( COPD - LUCSS ) [ J ]. Am J Respir CritCare Med,2014,12: 18 -25.
  • 2Umeyama H, Iwadate M,Taguchi YH. TINAGL1 and B3GALNT1are potential therapy target genes to suppress metastasis in non —small celllung cancer[ J]. BMC Genomics,2014,15(Suppl 9) :S2-10.
  • 3Righi L, Vavalcl T, Rapa I, et al. Impact of non - small cell lungcancer - not otherwise specified immunophenotyping on treatmentoutcome[ J]. J Thorac 0ncol,2014,9( 10) :1540 -1546.
  • 4Song R, Liu Q, Hutvagner G, et al. Rule discovery and distanceseparation to detect reliable miRNA biomarkers for the diagnosis oflung squamous cell carcinoma[ J]. BMC Genomics,2014,15(Sup-pl 9) :S16.
  • 5Rong B, Zhao C, Liu H, et al. Identification and verification ofHsp90 - beta as a potential serum biomarker for lung cancer[ J].Am J Cancer Res,2014,4(6) :874 -885.
  • 6Sriplung H,Bilheem S,Kuntipundee T,et al. Differences in cancerincidence among predominantly muslim and buddhist subpopula-tions in Songkhla [ J] . Asian Pac J Cancer Prev,2014,15 (22 ):9979 -9983.
  • 7Kravtsov V,Sukmanov I, Yaffe D,et al. Diagnostic aspects of fineneedle aspiration for lung lesions : Series of 245 cases [ J ]. AsianPac J Cancer Prev,2014,15.22) :9865 -9869.
  • 8Wang B,He YJ,Tian YX,et al. Clinical utility of haptoglobin incombination with CEA, NSE and CYFRA21 一 1 for diagnosis oflung cancer[ J]. Asian Pac J Cancer Prev,2014,15 (22) :9611 -9614.
  • 9Akbar S,Alsharidah MS. Are beta blockers new potential anticanceragents [ J ] . Asian Pac J Cancer Prev, 2014, 15 ( 22 ) ; 9567 -9574.
  • 10Aghanoori MR, Mirzaei B, Tavallaei M. MiRNA molecular profilesin human medical conditions : Connecting lung cancer and lung de-velopment phenomena [ J]. Asian Pac J Cancer Prev, 2014, 15(22):9557 -9565.

同被引文献62

  • 1陈允硕,吴健民.肿瘤标志物临床检测的基本原则(建议稿)[J].中华检验医学杂志,2004,27(6):393-393. 被引量:35
  • 2Siegel R,Deepa Naishadham MA MS,Ahmedin Jemal DVM PhD. Cancer statistics, 2013 [J]. Ca A Cancer Journal for Clinicians, 2013,63 ( 1 ) : 11-30.
  • 3Zheng X,Schipper M, Kidwell K, et al. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer:a recta-analysis [J]. Int J Radiat Oncol Biol Phys, 2014,90(3) : 603-611.
  • 4Reich JM. Lung-cancer screening [J]. N Engl J ged, 2005,353 (20) : 2194-2195.
  • 5Li X,Asmitananda T,Gao L,et al. Biomarkers in the lung cancer diagmosis:a clinical perspectinve [J]. Neoplasma, 2012,59(5) :500-507.
  • 6Gold P,Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques [J]. J Exp Med, 1965,121 (3) : 439-462.
  • 7Matsuoka K,Sumitomo S,Nakashima N,et al. Prognostic val- ue of carcinoembryonic antigen and CYFRA21-1 in pa- tients with pathological stage I non-small cell lung can- cer [J]. Eur J Cardiothorac Surg, 2007,32 (3) : 435-439.
  • 8Okamura K, Takayama K, Lzumi M, et al. Diagnostic val- ue of CEA and CYFRA 21-1 tumor markers in primary lung cancer [J]. Lung Cancer, 2013,80 ( 1 ) : 45-49.
  • 9Ando S,Kimura H,Iwai N,et al. The significance of tu- mour markers as an indication for mediastinoscopy in non-small cell lung cancer [J]. Respirology, 2003,8 (2) : 163-167.
  • 10Bast RC Jr,Feeney M,Lazarus H,et al. Reactivity of a monoclonal antibody with human ovarian carcinoma [J]. J CIin Invest, 1981,68(5) : 1331-1337.

引证文献8

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部